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OBJECTIVE — To determine whether real-time continuous glucose monitoring (CGM) with
preset alarms at speciﬁc glucose levels would prove a useful tool to achieve avoidance of hypo-
glycemia and improve the counterregulatory response to hypoglycemia in adolescents with type
1 diabetes with hypoglycemia unawareness.
RESEARCH DESIGN AND METHODS — Adolescents with type 1 diabetes with hy-
poglycemia unawareness underwent hyperinsulinemic hypoglycemic clamp studies at baseline
to determine their counterregulatory hormone responses to hypoglycemia. Subjects were then
randomizedtoeitherstandardtherapyorreal-timeCGMfor4weeks.Theclampstudywasthen
repeated.
RESULTS — The epinephrine response during hypoglycemia after the intervention was
greater in the CGM group than in the standard therapy group.
CONCLUSIONS — Agreaterepinephrineresponseduringhypoglycemiasuggeststhatreal-
timeCGMisausefulclinicaltooltoimprovehypoglycemiaunawarenessinadolescentswithtype
1 diabetes.
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H
ypoglycemia unawareness is deﬁned
as the onset of neuroglycopenia be-
fore autonomic activation (1). Pa-
tients have defective symptomatic and
counterregulatory responses, in particular
impaired epinephrine response to hypogly-
cemia. Both defective counterregulatory re-
sponses and hypoglycemia unawareness
constitute the hypoglycemia-associated au-
tonomic failure associated with recurrent
iatrogenic hypoglycemia (2–4).
In adults, it has been demonstrated
that as little time as 2 to 3 weeks of avoid-
anceofhypoglycemiareverseshypoglyce-
mia unawareness and improves the
attenuatedepinephrinecomponentofde-
fective counterregulation in affected pa-
tients (5–7). Although strict avoidance of
hypoglycemia can restore autonomic
symptoms of hypoglycemia and improve
counterregulatory responses to hypogly-
cemia, this is difﬁcult to achieve in prac-
tice. Real-time continuous glucose
monitoring (CGM) allows patients to
view their blood glucose levels almost in-
stantaneously and offers potential to re-
duce hypoglycemia frequency.
Thisstudywasdesignedtodetermine
whether real-time CGM with preset
alarms at speciﬁc glucose levels would
proveausefultooltoachieveavoidanceof
hypoglycemia and therefore improve the
counterregulatoryresponsetohypoglyce-
mia in adolescents with type 1 diabetes
with hypoglycemia unawareness.
RESEARCH DESIGN AND
METHODS— Adolescents with type
1 diabetes aged 12–18 years with hypo-
glycemia unawareness attending Princess
Margaret Hospital diabetes clinics were
invited to participate. Hypoglycemia un-
awareness score was determined by the
use of modiﬁed Clarke’s questionnaire
(8).Thisquestionnairehasbeenshownto
accuratelyidentifypatientswithimpaired
awareness of hypoglycemia for both clin-
ical and research purposes (9). A score of
8 is suggestive of hypoglycemia un-
awareness. Consent was obtained for all
participants.
All subjects underwent a hyperinsu-
linemic hypoglycemic clamp study at
baseline to assess hypoglycemic symp-
toms and hormonal responses. Subjects
were then randomized to either standard
therapy (standard group) or to the use of
real-time (Medtronic Minimed Paradigm
REAL-Time System) CGM (CGM group)
for 4 weeks. At the end of the 4-week
period, all patients underwent a repeat
hypoglycemic clamp study.
Hyperinsulinemic hypoglycemic
clamp
During this procedure, the antecubital
vein was cannulated for insulin and glu-
cose infusion, and blood was sampled
fromthecontralateralhandveinplacedin
a box heated to 60°C. Regular insulin
(Human Actrapid; Novo Nordisk, Craw-
ley,U.K.)wasinfusedataconstantrateof
80 mU/m
2/min. Target plasma glucose
levels were achieved by adjusting the rate
of infusion of 20% glucose in water.
Plasma glucose concentrations were
maintained initially at euglycemia (5–6
mmol/l) over a period of 1 h. Following
this, blood glucose was lowered over 30
min to a nadir of 2.8 mmo/l. The blood
glucose concentration of 2.8 mmol/l was
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miaphase.Euglycemiawasthenrestored.
For the duration of the clamp proce-
dure, blood glucose was analyzed at the
bedside using a glucose oxidase tech-
nique (YSI 2300; Yellow Springs Instru-
ments, Yellow Springs, OH). Additional
samplesofarterialisedvenousbloodwere
taken to measure plasma insulin, gluca-
gon, epinephrine, norepinephrine, corti-
sol, and growth hormone concentrations.
Study intervention
Following the ﬁrst hypoglycemic clamp
study, both groups were advised to
strictly avoid hypoglycemia with ﬁnger-
stick testing at least four to six times daily
to maintain blood glucose levels between
6and10mmol/lforthe4-weekperiod.In
addition, the CGM group wore real-time
CGMwithsubcutaneoussensorwithpre-
set low alarms at 6 mmol/l and was ad-
vised to institute standard hypoglycemia
treatmentforbloodglucoselevelsbelow6
mmol/l with target blood glucose level of
8 mmol/l.
The CGM group received an an addi-
tional2hofinstructionsregardingsensor
insertion and usage. Sensors were
changed every 3 days.
Outcome measures
The major outcome measure was the epi-
nephrine response to hypoglycemia mea-
sured during the hypoglycemia clamp
study. Plasma epinephrine levels were
measured by ELISA (Diagnostika GMBH,
Hamburg, Germany) and samples were
analyzed in duplicate. The interassay co-
efﬁcient of variation at 10 pmol/l and
5,460 pmol/l were 2% and 5.5%,
respectively.
RESULTS— Eleven subjects were
studied, including ﬁve subjects in the
standard group (age 15.0  0.8 years,
A1C 7.9  0.3% since diagnosis, dura-
tion 6.5  1.2 years) and six subjects in
the CGM group (age 13.8  0.7 years,
A1C 7.7  0.2% since diagnosis, dura-
tion 5.2  1.4 years).
At baseline, the epinephrine response
to hypoglycemia was blunted, and there
was no difference between subjects ran-
domized to standard or CGM groups
(percentage change 288  151 vs. 214 
72%, standard vs. CGM group, respec-
tively; P  0.688). Following the inter-
vention, there was a greater epinephrine
response in the CGM group (percentage
change 114  83 vs. 604  234%, stan-
dard vs. CGM group, respectively; P 
0.048). This represents a greater percent-
age rise in epinephrine concentrations
during hypoglycemia following therapy
in the CGM group (P  0.375 vs. 0.031,
standard vs. CGM group, respectively) as
showninFig.1.Peakadrenalineresponse
during hypoglycemia after the interven-
tion was also greater in the CGM group
than in the standard group (1,093  221
vs. 572  162 pmol/l; P  0.048). Sub-
jects in the CGM group reported higher
adrenergic symptoms scores after the in-
tervention than the standard group
(5.4  0.4 vs. 3.4  0.2; P  0.001).
The mean A1C at baseline was 7.9 
0.3% for both groups. Following the in-
tervention, there was no deterioration in
glycemic control in the standard or CGM
group (A1C 7.9  0.4 vs. 8.3  0.3%;
P  0.587).
The glucagon response was absent at
baseline and after intervention in both
groups. There was no change in cortisol
and growth hormone responses to hypo-
glycemia for both groups.
CONCLUSIONS— The epinephrine
response to hypoglycemia in patients
with type 1 diabetes with hypoglycemia
unawareness was greater after the use of
real-time CGM with low glucose alarms
than with standard medical therapy
alone.TheuseofCGMwasnotassociated
with deterioration in A1C. This greater
epinephrine response during hypoglyce-
mia suggests that real-time CGM is a use-
ful clinical tool to improve hypoglycemia
unawareness in adolescents with type 1
diabetes. The high risk of associated se-
vere hypoglycemia requires that hypogly-
cemia unawareness be recognized and
treated.
This study demonstrates that
blunted counterregulatory responses to
hypoglycemia do occur in adolescents
with a relatively short duration of dia-
betes. In addition to the blunted epi-
nephrine response, most of these
subjects reported no adrenergic symp-
toms during their baseline hypoglyce-
mic clamp study.
Alimitationofthisstudyisthesample
size. However, evaluating counterregula-
tory response with hypoglycemia clamp
studies is a robust method, and this tech-
nique limits inclusion of a large number
of subjects.
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